Skip to main content
Erschienen in: World Journal of Urology 4/2022

17.01.2022 | Original Article

Diagnostic performance of fusion (US/MRI guided) prostate biopsy: propensity score matched comparison of elastic versus rigid fusion system

verfasst von: Mariaconsiglia Ferriero, Gabriele Tuderti, Gian Luca Muto, Cristian Fiori, Alfredo Maria Bove, Riccardo Mastroianni, Umberto Anceschi, Leonardo Misuraca, Aldo Brassetti, Sabrina De Cillis, Enrico Checcucci, Salvatore Guaglianone, Michele Gallucci, Francesco Porpiglia, Giuseppe Simone

Erschienen in: World Journal of Urology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Many software for US/MRI guided fusion prostate biopsy (FPB), have been developed in the last years. However, there are few data comparing diagnostic accuracy of different fusion systems. We assessed diagnostic performance of elastic (EF) versus rigid fusion (RF) PB in a propensity score matched (PSM) analysis.

Methods

A total of 314 FPB were prospectively collected from two different centers. All patients were biopsy naïve and all mpMRI reported a single suspicious area. Overall, 211 PB were performed using a RF system and 103 using an EF software. The two groups were compared for the main clinical features. A 1:1 PSM analysis was employed to reduce covariate imbalance to < 10%. Detection rate (DR) for any prostate cancer (PCa) and clinically significant (cs) PCa were compared and stratified for PI-RADS Score. A per target univariable and multivariable regression analyses were applied to identity predictors of anyPCa and csPCa.

Results

After applying the PSM, two cohorts of 83 cases were selected. DR of any PCa cancer and csPCa were comparable between the two cohorts (all p > 0.077) as well as DR of csPCa for every PIRADS score. At univariable regression analysis lesion size, PI-RADS Score, PSA Density and EF system were predictors of any PCa (all p < 0.001); however, at multivariable analysis only PI-RADS Score was independent predictor of any PCa (p = 0.027). At multivariable analysis only PI-RADS score was independent predictor of csPCa.

Conclusions

Fusion PB guarantees high diagnostic accuracy for csPCa, regardless of the fusion technology. Prospective randomized study is needed to confirm these data.
Literatur
1.
Zurück zum Zitat Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020. Eur. Assoc. Urol. Guidel. 2020 Ed., vol. presented at the EAU Annual Congress Amsterdam 2020, Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020. Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020. Eur. Assoc. Urol. Guidel. 2020 Ed., vol. presented at the EAU Annual Congress Amsterdam 2020, Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020.
2.
Zurück zum Zitat Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822CrossRef Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822CrossRef
3.
Zurück zum Zitat Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777CrossRef Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777CrossRef
4.
Zurück zum Zitat Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S et al (2019) Comparison of targeted vs systematic prostate biopsy in men who are biopsy naive: the prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) Study. JAMA Surg 154:811–818CrossRef Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S et al (2019) Comparison of targeted vs systematic prostate biopsy in men who are biopsy naive: the prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) Study. JAMA Surg 154:811–818CrossRef
5.
Zurück zum Zitat Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL et al (2012) 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol 187:1080–1086CrossRef Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL et al (2012) 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol 187:1080–1086CrossRef
6.
Zurück zum Zitat Tewes S, Hueper K, Hartung D, Imkamp F, Herrmann TRW, Weidemann J et al (2015) Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results. World J Urol 33:1707–1714CrossRef Tewes S, Hueper K, Hartung D, Imkamp F, Herrmann TRW, Weidemann J et al (2015) Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results. World J Urol 33:1707–1714CrossRef
7.
Zurück zum Zitat Sonn GA, Margolis DJ, Marks LS (2014) Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol 32:903–911CrossRef Sonn GA, Margolis DJ, Marks LS (2014) Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol 32:903–911CrossRef
8.
Zurück zum Zitat Venderink W, de Rooij M, Sedelaar JPM, Huisman HJ, Fütterer JJ (2018) Elastic versus rigid image registration in magnetic resonance imaging–transrectal ultrasound fusion prostate biopsy: a systematic review and meta-analysis. Eur Urol Focus 4:219–227CrossRef Venderink W, de Rooij M, Sedelaar JPM, Huisman HJ, Fütterer JJ (2018) Elastic versus rigid image registration in magnetic resonance imaging–transrectal ultrasound fusion prostate biopsy: a systematic review and meta-analysis. Eur Urol Focus 4:219–227CrossRef
9.
Zurück zum Zitat Shoji S (2019) Magnetic resonance imaging-transrectal ultrasound fusion image-guided prostate biopsy: current status of the cancer detection and the prospects of tailor-made medicine of the prostate cancer. Investig Clin Urol 60:4–13CrossRef Shoji S (2019) Magnetic resonance imaging-transrectal ultrasound fusion image-guided prostate biopsy: current status of the cancer detection and the prospects of tailor-made medicine of the prostate cancer. Investig Clin Urol 60:4–13CrossRef
10.
Zurück zum Zitat Sokolakis I, Pyrgidis N, Koneval L, et al. Usability and diagnostic accuracy of different MRI/ultrasound-guided fusion biopsy systems for the detection of clinically significant and insignificant prostate cancer: a prospective cohort study. World J Urol 39: 4101–4108. Sokolakis I, Pyrgidis N, Koneval L, et al. Usability and diagnostic accuracy of different MRI/ultrasound-guided fusion biopsy systems for the detection of clinically significant and insignificant prostate cancer: a prospective cohort study. World J Urol 39: 4101–4108.
11.
Zurück zum Zitat Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A et al (2017) Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy-naïve patients with suspected prostate cancer. Eur Urol 72:282–288CrossRef Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A et al (2017) Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy-naïve patients with suspected prostate cancer. Eur Urol 72:282–288CrossRef
13.
Zurück zum Zitat Monda SM, Vetter JM, Andriole GL, Fowler KJ, Shetty AS, Weese JR et al (2018) Cognitive versus software fusion for MRI-targeted biopsy: experience before and after implementation of fusion. Urology 119:115–120CrossRef Monda SM, Vetter JM, Andriole GL, Fowler KJ, Shetty AS, Weese JR et al (2018) Cognitive versus software fusion for MRI-targeted biopsy: experience before and after implementation of fusion. Urology 119:115–120CrossRef
14.
Zurück zum Zitat Preisser F, Theissen L, Wenzel M, Humke C, Bodelle B, Köllermann J et al (2021) Performance of combined magnetic resonance imaging/ultrasound fusion-guided and systematic biopsy of the prostate in biopsy-naïve patients and patients with prior biopsies. Eur Urol Focus 7:39–46CrossRef Preisser F, Theissen L, Wenzel M, Humke C, Bodelle B, Köllermann J et al (2021) Performance of combined magnetic resonance imaging/ultrasound fusion-guided and systematic biopsy of the prostate in biopsy-naïve patients and patients with prior biopsies. Eur Urol Focus 7:39–46CrossRef
15.
Zurück zum Zitat Westhoff N, Siegel F, Peter C, Hetjens S, Porubsky S, Martini T et al (2019) Defining the target prior to prostate fusion biopsy: the effect of MRI reporting on cancer detection. World J Urol 37:327–335CrossRef Westhoff N, Siegel F, Peter C, Hetjens S, Porubsky S, Martini T et al (2019) Defining the target prior to prostate fusion biopsy: the effect of MRI reporting on cancer detection. World J Urol 37:327–335CrossRef
16.
Zurück zum Zitat Oderda M, Marra G, Albisinni S, Altobelli E, Baco E, Beatrici V et al (2018) Accuracy of elastic fusion biopsy in daily practice: results of a multicenter study of 2115 patients. Int J Urol Off J Japanese Urol Assoc 25:990–997 Oderda M, Marra G, Albisinni S, Altobelli E, Baco E, Beatrici V et al (2018) Accuracy of elastic fusion biopsy in daily practice: results of a multicenter study of 2115 patients. Int J Urol Off J Japanese Urol Assoc 25:990–997
17.
Zurück zum Zitat Westhoff N, Siegel FP, Hausmann D, Polednik M, von Hardenberg J, Michel MS et al (2017) Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms. World J Urol 35:1015–1022CrossRef Westhoff N, Siegel FP, Hausmann D, Polednik M, von Hardenberg J, Michel MS et al (2017) Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms. World J Urol 35:1015–1022CrossRef
18.
Zurück zum Zitat Park MY, Park KJ, Lim B, Kim M-H, Jeong IG, Kim JK (2020) Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway. Abdom Radiol 45:4166–4177CrossRef Park MY, Park KJ, Lim B, Kim M-H, Jeong IG, Kim JK (2020) Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway. Abdom Radiol 45:4166–4177CrossRef
Metadaten
Titel
Diagnostic performance of fusion (US/MRI guided) prostate biopsy: propensity score matched comparison of elastic versus rigid fusion system
verfasst von
Mariaconsiglia Ferriero
Gabriele Tuderti
Gian Luca Muto
Cristian Fiori
Alfredo Maria Bove
Riccardo Mastroianni
Umberto Anceschi
Leonardo Misuraca
Aldo Brassetti
Sabrina De Cillis
Enrico Checcucci
Salvatore Guaglianone
Michele Gallucci
Francesco Porpiglia
Giuseppe Simone
Publikationsdatum
17.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2022
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-021-03921-0

Weitere Artikel der Ausgabe 4/2022

World Journal of Urology 4/2022 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.